Merck to Buy Terns for $6.7B to Grow in Blood Cancers

Bloomberg's Michelle Davis joins Dani Burger on "Bloomberg Deals." Merck agreed to buy Terns Pharmaceuticals for $6.7 billion, giving the multinational company access to a promising new leukemia treatment as it faces the patent expiration of its bestselling cancer drug. (Source: Bloomberg)...

Redirecting to full article...